Processa Pharmaceuticals Inc Stock Price, News & Analysis

Processa Pharmaceuticals (Nasdaq: PCSA) has successfully dosed the first patient in its 300 mg group for the NGC-Capecitabine trial, a crucial step for assessing drug exposure against adverse events for FDA approval. This innovative chemotherapy aims to improve treatment outcomes without the severe side effects commonly associated with capecitabine, such as hand-foot syndrome and cardiotoxicity, which occur in 50-70% of current patients. The company anticipates FDA guidance on its Phase 2B trial in mid-April, enhancing collaboration under Project Optimus Oncology. The enrollment for the Phase 1B trial is expected to complete by mid-2023, with hopes of commencing the Phase 2B trial in the second half of the year.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced that President & CEO, Dr. David Young, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 12:00 PM Eastern. The presentation will be available via a live webcast on the company’s Investor Relations website. Processa is focused on developing Next Generation Chemotherapy drugs with improved safety and efficacy compared to existing FDA-approved options. Their pipeline includes Next Generation Capecitabine, Gemcitabine, and Irinotecan, targeting various cancers like colorectal, breast, and pancreatic.

For more information, visit Processa's website.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) emphasizes its focus on Next Generation Chemotherapies (NGCs), which are modifications of existing FDA-approved cancer treatments to enhance safety and efficacy. Clinical studies suggest NGCs could benefit more patients compared to traditional chemotherapy options like capecitabine and gemcitabine. The company plans FDA meetings in 2023 to discuss development phases and the implementation of Project Optimus. Processa is also exploring partnerships for non-oncology assets while prioritizing clinical trials for three specific NGCs aimed at treating various cancers.

Processa Pharmaceuticals (Nasdaq: PCSA) has successfully closed a $6.25 million registered direct offering of 7,812,544 common shares at $0.80 each. The offering was facilitated by Spartan Capital Securities, LLC, providing funds intended for future clinical trials, research and development, and general corporate needs. This transaction is part of a shelf registration filed with the SEC, allowing efficient capital raising. Processa aims to enhance treatment options for patients with unmet medical needs through its next-generation chemotherapy drugs.

Processa Pharmaceuticals (Nasdaq: PCSA) has announced a registered direct offering of 7,812,544 common shares at $0.80 each, aiming to raise approximately $6.25 million. The offering is set to close around February 14, 2023, pending standard conditions. Proceeds will be allocated to future clinical trials, research and development, and general corporate purposes. Spartan Capital Securities, LLC is acting as the placement agent. The shares will be offered under a previously filed effective shelf registration statement with the SEC. Processa focuses on developing innovative chemotherapy drugs to address unmet medical needs.

Processa Pharmaceuticals (Nasdaq: PCSA) will present its strategic focus at the Biotech Showcase on January 11, 2023, at 10 AM. CEO Dr. David Young will detail the company's therapeutic direction and engage with potential investors during the J.P. Morgan Annual HealthCare Conference week. The firm aims to meet the needs of patients with unmet conditions through its clinical pipeline, including treatments for various cancers and gastrointestinal disorders. Forward-looking statements highlight possible risks and uncertainties in achieving future milestones.

Processa Pharmaceuticals (Nasdaq: PCSA) reported positive results from a Phase 2A study of PCS12852 for treating gastroparesis. The 0.5 mg daily dose over 28 days significantly improved symptoms, with a greater percentage of patients achieving clinically meaningful reductions compared to placebo. Notably, 100% of patients on the 0.5 mg dose saw improvements. The study also indicated that longer treatment durations may yield even better results. These findings support the initiation of a Phase 2B trial in 2023.

Processa Pharmaceuticals (PCSA) reports positive preliminary results for PCS12852, which shows a significant effect on gastric emptying rates, leading to a Phase 2B trial planned for 2023. Additionally, the Next Generation Capecitabine (PCS6422) has identified effective dosing regimens for its Phase 2B trial after a successful FDA meeting. Financially, the company reported a net loss of $14.4 million for the nine months ending September 30, 2022, with cash reserves of $9.1 million, projected to fund operations into Q3 2023.

Processa Pharmaceuticals (PCSA) announced positive results from its Phase 2A Proof-of-Concept trial for PCS12852, a treatment for gastroparesis. The trial demonstrated a statistically significant improvement in gastric emptying among patients receiving a 0.5 mg dose compared to placebo, with a p-value of <0.10. Adverse events were mild to moderate, with no serious cardiovascular issues reported. Processa plans to evaluate PCS12852's effects on gastroparesis symptoms by year-end and initiate a Phase 2B trial in 2023.